

Polymorphism analysis of malaria susceptibility biomarkers in G6PD deficiency patients

Mohammad Reza Noori-dalooi¹, Mohammad Reza Alivand², Parisa Atef-Vahid³
Feyzollah Hashemi-Gorji⁴, Mehrdad Hashemi⁵

Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Received: 6 May 2010

Revised: 9 June 2010

Accepted: 19 June 2010

Abstract

Background: Several studies suggested that some traits and polymorphisms in human genome such as G6PD deficiency and other genes have protective effects on susceptibility to malaria infection.

Methods: In present study we investigated the prevalence of TNF α -244G \rightarrow A, TNF α -308G \rightarrow A, TNF α -238G \rightarrow A, NOS2-954G \rightarrow C, MBL54G \rightarrow A, MBL 57G \rightarrow A, MBL IVS-I-5G \rightarrow A polymorphisms and G6PD variants (Mediterranean, Chatham, Cosenza, A-(202,376) in 315 subjects with G6PD deficiency and 10 malaria patient. All the 315 subjects were selected from five provinces (Fars, Khuzestan, Esfahan, Yazd and Kerman) and screened by PCR-RFLP method.

Results: The NOS2-954G \rightarrow A consisted GG(40.31%), GC(53.01%), and CC(6.66%) where as TNF α -308 consisted GG(68.8%), AG(31.11%) contents. The TNF α -244 showed GG(94.60%), AG(5.39%) genotypes and the TNF α -238 had GG(92.69%), AG(6.66%), AA(0.63%) genotypes. The MBL54 polymorphism had GG(75.55%), AG(24.44%), AA(0.63%) genotypes. In MBL 57, had GG(95.23%), AG(4.76%), AA(0.63%) genotypes. The G6PD variants was indicated that Mediterranean mutation in Fars, Khuzestan, Esfahan, Yazd and Kerman provinces was 79.4%, 58%, 83/8%, 64% and 63% respectively and also, the Chatham mutation was 8.8%, 8%, 4.5%, 3.6% and 0% respectively. Analysis of other four mutations (Cosenza, Arures and A-202 and A-367) showed that none of them had those mutations.

Conclusion: Our results suggested that genotypes which causes protection against malaria or reduction of risk for cerebral malaria and death has the maximum prevalence in samples taken from the five provinces, but in the kolmogorov-smiranov test results, only NOS2-954G \rightarrow C supported the theory of relation between these polymorphisms and protection against malaria.

Keywords: G6PD, polymorphism, PCR-RFLP, TNF α , MBL2, NOS2, mediterranean, Chatham and Cosenza.

Introduction

Malaria is an infectious disease caused by protozoan parasites. More than half of the world's population in approximately 100 countries is exposed to malaria with about one mil-

lion deaths annually [1-3]. Iran is located in the Eastern Mediterranean region, where about 45% of the population live with the risk of having both falciparum and vivax malaria. The malaria endemic areas of Iran are located in the south-eastern part of the country, bordered in

1. **Corresponding author**, Professor, Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Pour Sina Ave., Tehran, Iran. Post Box: 14155-6447. Email: nooridalooi@sina.tums.ac.ir, Tel/fax: +9821 88953005

2. Instructor, Departments of Medical Genetics, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, Iran. Email: mohammadreza_alivand@yahoo.com

3. Instructor, Departments of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran. Email: atef_vahid@yahoo.com

4. Instructor, Department of Genetics, Science and Research Branch, Islamic Azad University, Tehran, Iran. Email: f.hashemigorji@gmail.com

5. Assistant Professor, Departments of Molecular Genetics, Islamic Azad University, Tehran Medical Branch, Tehran, Iran. Email: hashemi_mehrdad@yahoo.com

the south by the Persian Gulf and the Gulf of Oman and to the east by Afghanistan and Pakistan. The south-eastern part of Iran consists of the Sistan and Bluchistan province, the Hormozgan province and the tropical part of Kerman province with a combined population of approximately three millions and is considered to be a "refractory malaria region". Annual Parasite Incidence (API) was reported to be 8.74 per 1,000 population [1]. High frequency of some traits in malaria endemic areas suggested the strong selective pressure of malaria on human genome. These traits consist of: thalassemia, HLA antigens, and G6PD deficiency which are common in many areas, and have been shown to be related with the reduced susceptibility to severe malaria and the G6PD deficiency is indicated to be more important than others. This gives the selective advantage against severe malaria since prevalence of the G6PD deficiency has had 5% to 25% increase in comparison with other areas in malaria endemic area. The glucose 6-phosphatase dehydrogenase is X-chromosome linked expressing in all tissues. This is the first enzyme of pentose phosphate pathway with 5-carbon sugar ribose and NADPH synthesized by coupled oxidation/reduction reactions. Moreover this enzyme is highly polymorphic in humans by which more than 160 different mutations have been identified so far. In addition, genetic variations in several other genes, including TNF α , MBL and NOS2 have been identified. The tumor necrosis factor-alpha (TNF α) is a key cytokines with an important role in pathogenesis of severe infectious diseases. The genetic susceptibility to severe form of malaria (cerebral malaria) is associated with TNF α promoter polymorphisms and high circulating levels of cytokines. Nonetheless the level of nitric-oxide (NO), which is related to polymorphisms in NOS2 gene, could play an important role in severity of many diseases including malaria. Mannose-binding lectin (MBL) is thought to play an important role in the innate immune defense. The

ligands of MBL are high in mannose and N-acetylglucosamine oligosaccharides that presented on a variety of microorganisms. At present study, we investigate the frequency of common polymorphisms in NOS2 (1 polymorphism), MBL2 (3 polymorphisms), TNF α (3 polymorphisms) genes and G6PD (4 variants) which is related to protection against malaria in 315 healthy samples with G6PD deficiency and 10 samples of malaria patients without G6PD deficiency in five provinces (Fars, Khozestan, Esfahan, Yazd and Kerman) [13,31].

Methods

Study population and area: We collected 315 samples from non related healthy subjects with G6PD deficiency and 10 samples from patients who were hospitalized with the sign of malaria and their blood smears showed presence of the parasite. All samples were collected from Fars (34 samples), Khuzestan (100 samples), Esfahan (62 samples), Yazd (55 samples) and Kerman (64 samples) provinces of IRAN which comprised 30% of disease incidence of country. Informed consent was obtained from the subjects before sampling. All of the 315 samples had G6PD deficiency using dye reduction test.

DNA extraction: Genomic DNA was extracted from white blood cells using standard methods of DNA extraction (Phenol Chloroform and southing out).

DNA polymorphism analysis: All collected samples including the Mediterranean, Chatham, Cosenza, Aures and A-(376,202) variants were evaluated by DNA amplification with specific primer and digestion with restriction enzyme endonuclease (Table1). Amplification of DNA samples from Mediterranean, Chatham, Cosenza, A-(376,202) and Aures variants were 583bp, 208bp, 548bp, 295bp, 108bp and 352bp, respectively. To detect the genetic polymorphism of the NOS2-954 a 680-bp fragment of NOS2 promoter region was amplified. To detect TNF α

Table1. The polymorphisms and variants with specific primers and restriction enzymes.

<i>Polymorphism and Variants</i>	<i>Primer sequence</i>	<i>Annealing temperature (°C)</i>	<i>Restriction Enzyme</i>
G6PD-med	Med- F 5'CCCCGAAGAGGAATTCAAGGGGGT-3' Med- R 5'-GAAGAGTAGCCCTCGAGGGTGACT-3'	61	MboII
G6PD-Chat ^{G1003A}	Chat-F 5' CAA GGA GCC CAT TCT CTC CCT T 3' ChatR5'-TTCTCCACATAGAGGACGACGGCTGCCA AAGT-3'	60	BstXI
G6PD-Coz ^{G1367C}	Coz F-5'-GCA GGC AGT GGC ATC AGC AAG -3' Coz R: 5'-GGG AAG GAG GGT GGC CGT GG -3' A202 F 5'-GTGGCTGTTCCGGGATGGCCTTCTG- 3'	64	Bsu36I
G6PD A ⁻ (G202A)	A202 R :5' CTTGAAGAAGGGCTCACTCTGTTTG-3' A375 :5'CTGTCTGTGTGTCTGTCTGTCC3' A375R: 5' GGCCAGCCTGGCAGGCGGGAAGG3' CAGCCACTTCTAACCACACACCT 3 5'-CCGAAGCTGGCCATGCTGGG 3	56	Nla III
G6PD A ⁻ (A375G)	TNFα1:5'-GGCAATAGGTTTGGAGGGCCATG-3' TNFα 2:5'-CACACTCCCCATCCTCCCTGATC-3'	61	FokI
G6PD Aures	TNFα 1 and TNFα 2	58	Bgl II
TNFα-308G→A	TNFα 1 and TNFα 2	58	NcoI
TNFα-244G→A	MBL1:5'-CAGGCAGTTTCTCTGGAAGG-3' MBL2:5'-GCACCCAGATTGTAGGACAGAG-3'	58	HpyF3II
TNFα-238G→A	MBL1 and MBL2	60	BspPI
MBL 54G→A	MBL1 and MBL2	60	BshNI
MBL 57G→A	MBL1 and MBL2	60	MboII
MBL IVS-I-5G→A	NOS2 1:5'-TGTTGGGACGGTGAGATCAAGGT-3' NOS2 2:5'-CTCATCAAAGGTGGCCGAGAGAT-3'	60	Hin1II
NOS2-954G→C		62	Eco3II

polymorphisms a 117-bp fragment of promoter region was amplified and next to detect MBL2 polymorphisms a 340-bp fragment amplified. PCR amplification was done using 2µl of DNA in a total volume of 50µl reaction mixture containing appropriate primers (Table1). The amplified products were analyzed on 10% agarose gel and visualized with ethidium bromide staining. Eight micro liters of each amplified products was digested with 15 µl of reaction mixture containing 1U of appropriate restriction enzyme (Table1). Inactivation of enzyme was performed with proteinase K after 1-12 hours incubation and the digestion solutions analyzed on 12% acrylamide gel and later visualized with silver-nitrate staining.

Statistical analysis: the two-sample kalmogorov-smiranov test was used to compare the distribution of host genetic variants in individuals

with and without malaria.

Results

All the 315 subjects were screened through PCR-RFLP analysis for TNFα-244G→A, TNFα-308G→A, TNFα-238G→A, NOS2-954G→C, MBL54G→A, MBL 57G→A, MBL IVS-I-5G, G6PD-med, G6PD-Chat, G6PD-Coz, G6PD A- (G202A), G6PD A-(A375G) and G6PD Aures. The frequency of NOS2-954G→A showed that 127 out of 315 (40.31%) healthy samples had GG genotype, 167 samples (53.01%) GC and 21 samples (6.66%) CC. All the 10 samples from malaria patients showed GG genotype. In TNFα-308, 217 out of 315 (68.8%) samples showed GG genotype, 98 samples (31.11%) AG genotype but none had AA. For TNFα-244, 298 of samples (94.60%) showed GG genotype, 17 samples (5.39%) AG genotype and




Fig. 1. Restriction digestion analysis of PCR products for TNF-244G→A, TNF-238G→A and TNF-308G→A polymorphisms with HpyF31I, BspPI and NcoI enzymes respectively on acrylamid gel. There are 117 pb fragment in all three polymorphism. Lane 2,3:GG genotype of TNF-244 polymorphism with 117 bp ; Lane 4,6: GG genotype of TNF-238 polymorphism with 117bp; Lane9,10: AG and GG genotypes of TNF-308 polymorphism with 117bp,94bp,23bp and 94bp,23bp respectively; lane 1,5 and 8: Size marker of DNA (100bp ladder).

none had AA. All malaria patients showed GG genotype in this region. In TNF α -238, 292 of samples (92.69%) showed GG genotype, 21 samples (6.66%) AG genotype and 2 of the samples(0.63%) AA genotype and all of malaria patients had GG genotype in this region. In MBL54, 238 samples (75.55%) had GG genotype, 77 samples (24.44%) AG genotype and 2 samples (0.6%) AA genotype. 2 samples of

malaria patients (20%) had AG genotype and 80% GG genotype. In MBL 57, 300 samples (95.23%) had GG genotype, 15 samples (4.76%) AG genotype and 2 samples (0.63%) AA genotype. eight samples (80%) of malaria patient GG genotype and 20% AG genotype. in MBL IVS-I-5G→A, All 315 samples showed (100 %) GG genotype and all malaria patients showed GG polymorphism. In studding of




Fig. 2. Restriction digestion analysis of PCR products for MBL IVS-I-5, MBL54 and MBL57 polymorphisms with Hin1II, BshNI and MboII enzymes respectively on acrylamid gel. All of them have 340 pb fragment as a PCR product. Lane 1,2: AG genotype and PCR product of MBL IVS-I-5 polymorphism with 240, 71, 28bp and 340bp respectively; Lane 5,6,7: GG,AA and AG genotypes of MBL54 polymorphism with (340bp), (256,84) and (340,256,84) 287,62; Lane 8,6: GA and GG genotype of MBL57 polymorphism with (340,287,62) and 340bp; lane 3,4 and 10: Size marker of DNA (100bp ladder)




Fig. 3. Restriction digestion analysis of PCR products for NOS2-954G→C polymorphism with Eco31I enzyme on acrylamid gel. Lane 2,3: GG genotype of NOS2-954G→C polymorphism with 487and 190bp, Lane 4: CG genotypes of NOS2-954G→C polymorphism with 677,487, 190bp and Lane 1: Size marker of DNA (100bp ladder).




Chart 1. Distribution of NOS2-954 alleles in healthy individuals and patients.

367(A→G) and Aures (T→C) in which none had these mutations.

Difference between distribution of each genotype variants in healthy and patients objects was studied by two-samplekalmogorov-smiranov test, to find the relation between these genotype and protection against malaria. Only distribution of NOS2-954C (p=0.002 by two-samplekalmogorov-smiranov test) supported this theory.

G6PD variant indicated that Mediterranean mutation in Fars, Khuzestan, Esfahan, Yazd and Kerman provinces was 79.4%, 58%, 83/8%, 64% and 63% respectively. Also, Chatham mutation was 8.8%,8% 4.5%, 3.6% and 0% respectively. Finally, other four mutations analyzed were Cosenza, A-202(G→A), A-

Discussion

Malaria is known to be a dangerous and tremendously successful pathogen that is responsible for 300 million cases of infection with and one million deaths annually [3,4]. Plasmodium falciparum is the causative agent




Fig. 4. Restriction digestion analysis of PCR products for G6PD Mediterranean, Chatham, Cosenza, A-376, A-202 mutation with length of 583bp, 208bp, 548bp, 295bp, 108bp and 352bp, respectively, as a PCR products and was digested by MboII, BstXI, Bsu36I, FokI and Nla III enzymes on acrylamid and agarose gel.




Chart 2. Distribution of TNF α -244 alleles in healthy individuals and patients.




Chart 3: Distribution of TNF α -308 alleles in healthy individuals and patients objects.

in more than one million children in Africa. Other species of this parasite, *p. vivax*, *p. Malariae*, *p. Ovale*, can also infect humans. The genetic diversity of the parasite, generated by its sexual stage, provides the organism with many opportunities to maximally adapt to host defenses and continue transmission. Due to the length of exposure time, and significant effects on morbidity and mortality by infection, it has exerted a strong selective pressure on the human genome, and causes mutations in human genes which promote survival in areas where malaria is endemic [33]. Protection against this microorganism is provided with the polymorphisms generated in the human genome after many generations [32]. Large numbers of these polymorphisms have been found in genes which codes erythrocytes protein and cytokines. The relation between some human traits and severity of malaria infection, has been well documented [34]. These traits mainly found in red blood cell disorders like sickle cell anemia, thalassemia and other traits like G6PD

deficiency [35,36]. The protection against malaria is suggested to be related to polymorphisms in more than 30 genes [1]. Investigations have indicated that a number of variants are involved including those of the major histocompatibility complex and a cytokine-gene cluster on Chromosome 5q31-q33 [38, 39].

The TNF α codes by TNF genes located in MHC class III nearby MHC class I and II, and is a pro-inflammatory cytokine that plays an essential role in the protection against many infections including malaria, but also fatal when produced in excess [41, 42]. A study on Burkina Faso families revealed the linkage of mild malaria to the MHC region genes with a peak close to TNF [43]. Variety of polymorphisms in promoter region of TNF gene are related to severity of infectio. It has revealed that Gambian childrens who harbor homozygous TNF-308A allele are more susceptible to cerebral malaria [9]. Other studies in Gabon, Serilanka and kenia suggested individual who carries this allele are more susceptible to recurrence of




Chart 4. Distribution of MBL254 alleles in healthy individuals and patients.




Chart 5: Distribution of TNF α -238 alleles in healthy individuals and patients.




Chart 6. Distribution of MBL57 alleles in healthy individuals and patients.




Chart 7. Distribution of MBL IVS-I-5 alleles in healthy individuals and patients.

plasmodium infection or death [45,46]. The TNF-376A play role in binding to transcription factor, OCT-1 and susceptibility to the cerebral malaria, and the TNF-238A is related to susceptibility to the malarial anemia. Nevertheless, results about the role of TNF polymorphisms in protection against malaria are conflicting [9, 47].

Several findings suggested single nucleotide polymorphisms (SNPs) in 5' regulatory site of TNF gene and in coding region of FCGR2A are associated with susceptibility to plasmodium falciparum Malaria [9,49,50,52]. The tumor necrosis factor alpha (TNF) have role in many inflammatory responses and also play an important role in pathogenesis of many infectious diseases such as plasmodium falciparum Malaria [10]. Transcription of TNF gene is complex and well regulated [55], and it has revealed that SNPs in 5' regulatory region of this gene are related with variety of infectious and inflammatory diseases [56,57]. SNPs in -1031, -857, -376 (1800750,G>A), -308 and -238 are located in regulatory region of TNF gene and associated with TNF production as well as protection against Malaria in different populations [50,52,49,60,61]. Taking this, it seems important to discover TNF special responses. A study on polymorphisms of TNF-enhancer and gene for FcγRIIa correlate with the severity and diversity of falciparum malaria in the ethnically diverse Indian population [61]. This differences has been also reported in 17 regions of Africa and Burkina Faso [62,21,25].

In our study three polymorphisms in promoter region of TNF α gene were analyzed based on the two-sample kalmogorov-smiranov test.

Comparison of genotype frequency for the TNF α polymorphisms, between healthy people and malaria patient revealed no significant difference ($p>0.01$).

Several studies suggested that the presence of the different variant alleles in the MBL gene is associated with an increased tendency for infections [7,27,28]. According to two-sample kalmogorov-smiranov test, no association in frequency distribution of MBL variant alleles and susceptibility to malaria infection was found. A study among Gambian children also, has shown no relation between MBL deficiency and malaria [29]. Another study among young Gabonese children has found a weak correlation between the MBL deficiency and severe malaria [23]. This study also suggested the MBL deficiency may not be associated with malaria, but it could be a risk factor for severe malaria in children who lack well developed protective acquired immune responses [30].

Nitric oxide has been determined to possess antiparasitic activity [31], and our results shown an association between NOS2-954GC alleles and susceptibility to malaria ($p=0.002$ by two-sample kalmogorov-smiranov test). A study among Gabonian individuals shown heterozygous carriers for NOS-G954C are protected against malaria as effectively as sickle cell trait [8]. Another study showed no significant difference in multiplicity of infection between

children who were heterozygous for NOS2-954C and those with wild type alleles [23].

We found that the G6PD Mediterranean, was the most common G6PD deficient variant in these five provinces, which accounts for 69.56% of the 315 analyzed samples. Similar to other parts of Iran [13,23], in the majority of the people in these provinces, favism is most probably due to Gd-Med, which may suggest a common origin for the populations in Iran and the Mediterranean. It should be emphasized also that G6PD Mediterranean frequency reached 91.2% in Kermanshah province [23]. Our data showed that on the average, in Iranian population, the Chatham mutation was the next one in five provinces, and accounts for 4.95% [23]. Although the origin of the Iranian population is rather uncertain, but the closer similarity of the mutational spectrum to Italian (80-84% for Mediterranean, 20% for Chatham and 1.9% for Cosenza) rather than Middle East population may indicate a common ancestral origin [7-25,3-34].

Acknowledgments

This work supported by grants from the National Research Center for Genetic Engineering and Biotechnology (NRCGEB) and Tehran University of Medical Sciences and health services, Tehran, Iran.

References

1. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. *Nature* 2002; 15:673-679.
2. Zakeri S, Talebi-Najafabadi S. Detection of malaria parasites by nested-PCR in south-eastern, Iran: Evidence of highly mixed infections in Chahbahar district, *Malaria Journal* 2002;1: 1475-79.
3. Alilison AC. Protection afforded by sickle-cell trait against subterian malaria infection. *BMJ* 1954; 1:290-294.
4. Berman JG, Holloway CN. Malaria surveillance counts. *Am J Trop Med Hyg* 2007; 77: 36-47.
5. Nagel RL, Roth EF. Malaria and red cell defects. *Blood* 1989; 74: 1213-1221.

6. Hill AV, Allsopp CEM, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, et al. Common West African HLA antigens are associated with protection from severe malaria. *Nature* 1991; 352: 595-600.

7. Garred P, Nielsen MA, Kurtzhals JAL, Malhotra R, Madsen HO, Goka BQ, et al. Mannose binding lectin is a disease modifier in clinical malaria and may function as opsonin for plasmodium falciparum infected erythrocytes. *Ifec & Immu* 2003; 5245-5253.

8. Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, et al. Nitric oxide synthase 2 (Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. *J Infect Dis* 2001; 184: 330-6.

9. Mc-Guire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. *Nature* 1994; 6: 508-10.

10. Butler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. *Critical Care Medicine* 1993; 21: 423-435.

11. Cramer JP, Nussler AK, Ehrhardt S, Burkhardt J, Otchwemah RN, Zanger P, et al. Age-dependent effect of plasma nitric oxide on parasite density in Ghanaian children with severe malaria. *Trop Med Int Health* 2005; 10(7): 672-80.

12. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summerfield J.A, et al. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. *Hum Mol Genet* 1992; 1: 709-715.

13. Noori-Dalooi MR, Hejazi SH, Yousefi A, Mohammadganji S, Soltani S, Javadi KR, et al. Identification of Mutations in G6PD Gene in patients in Hormozgan Province of Iran. *J Sci I R Iran* 2006; 17(4): 215-219.

14. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW et al. Molecular basis of opsonic defect in immunodeficient children. *Lancet* 1991; 337: 344-353.

15. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. *J Exp Med* 1992; 176: 1497-1503.

16. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. *Immunol Today* 1996; 17: 532-540.

17. Sastry K, Herman GA, Day L, Deignan E, Bruns G, Morton CC, Ezekowitz RAB. The human mannose-binding protein gene: Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. *J Exp Med* 1989; 170: 1175-1189.

18. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospi-

tal series. *BMJ* 1997; 314: 1229-1232.

19. Wilson AG, di Giovine FS, Blakemore AL, Duff GW. Single base polymorphism in the human tumor necrosis factor alpha gene detectable by Nco1 restriction of PCR product. *Hum Med Genet* 1992; 1: 353-559.

20. Zimmerman PA, Guderian RH, Nutman TB. A new TNF A promoter allele identified in south American Blacks. *Immunogenetics* 1996; 44: 485-486.

21. D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNF A promoter region. *Immunogenetics* 1994; 39: 150-154.

22. Ackerman H, Usen S, Mott R et al. Haplotypic analysis of the TNF locus by association efficiency and entropy. *Genome Biol* 2003; 4: 424-429.

23. Mombo L.E, Ntoumi F, Bisseye C, Ossari S, Lu Ch, L.Nagel R, Krishnamorthy R. Human genetic polymorphism and asymptomatic Plasmodium Falciparum malaria in Gabonese schoolchildren. *Am J Trop Med Hyg* 2003; 68(2): 186-190.

24. Kun JFJ, Mormuller B, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. *Lancet* 1998; 351: 265-266.

25. Flori L, Delahaye NF, Iraqi FA, Hernandez-valadare M, Fumoux F, Rihet P. TNF as a malaria candidate gene: polymorphism-screening and family-based association analysis of mild malaria attack and parasitemia in Burkina Faso. *Genes and Immunity* 2005; 6: 472-480.

26. Knight JC, Udalova I, Hill AVS, Greenwood BM, Peshu N, Marsh K, et al. polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. *Nat Genet* 1999; 22: 145-150.

27. Noori-Dalooi MR, Soltanian S, Mohammad-Ganji SH, Yousefi A, Hejazi S, Bani-hashem A, et al. Molecular Identification of the Most Prevalent Mutation of Glucose -6- Phosphate Dehydrogenase (G6PD) Gene in Deficient Patients in Sistan and Balochistan Province of Iran. *J Sci IR* 2006; 17(2): 103-106.

28. Garred P, Madsen HO, Hofmann B, Svejgaard A. Increased frequency of homozygosity of abnormal mannan-binding protein alleles in patients with suspected immunodeficiency. *Lancet* 1995; 346: 941-943.

29. Bellamy R, Ruwende C, McAdam KPWJ, Thursz M, Sumiya M, Summerfield J, et al. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. *Q J Med* 1998; 91: 13-18.

30. Luty AJF, Kun JFJ, Kremsner PG. Mannose-binding lectin plasma levels and gene polymorphisms in Plasmodium falciparum malaria. *J Infect Dis* 1998; 178: 1221-1224.

31. Noori-Dalooi MR, Hajebrahimi-Najafi L, Mesbah-Namin Z, Mowjoodi A, Mohammad-Ganji S, Yekaninejad MS, et al. Comprehensive study on the major mu-

tations in glucose-6-Phosphate dehydrogenase-deficient polymorphic variants identified in the Coastal Provinces of Caspian sea in North of Iran, *Clinical Biochemistry* 2007; 40: 699-704.

32. Campino S, Kwiatkowski D, Dessein A. Mendelian and complex genetics of susceptibility and resistance to parasitic infections. *Semin Immunol* 2006; 18: 411-22.

33. Daily JP, Sabeti PA. Malaria Fingerprint in the Human Genome. *engl j med* 2008; 358: 17-24.

34. Kwiatkowski D. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am J Hum Genet* 2005; 77: 171-192.

35. Tishkoff SA, Varkonyi R, Cahinhinan N, Abbes S, Argyropoulos G, Destro-Bisol, et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. *Science* 2001; 293: 455-462.

36. Williams TN, Wambua S, Uyoga S, Macharia A, Mwacharo JK. Both heterozygous and homozygous β -thalassemia protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. *Blood* 2005; 106: 368-371.

37. Timmann C, Evans JA, König IR, Kleensang A, Ruschendorf F, Lenzen J, et al. Genome-wide linkage analysis of malaria infection intensity and mild disease. *PLOS Genet* 2007; 23: 393-400.

38. Sengupta S, Farheen S, Mukherjee N, Dey B, Mukhopadhyay B, Sil SK, et al. DNA sequence variation and haplotype structure of the ICAM1 and TNF genes in 12 ethnic groups of India reveal patterns of importance in designing association studies. *Am J Hum Genet* 2003; 68: 574-587.

39. Sukumar S, Mukherjee MB, Colah RB, Mohanty D. Molecular basis of G6PD deficiency in India. *Blood Cells Mol Dis* 2004; 33: 141-145.

40. Balgir RS. Do tribal communities show an inverse relationship between sickle cell disorders and glucose-6-phosphate dehydrogenase deficiency in malaria endemic areas of Centraleastern India. *Homo* 2006; 57: 163-176.

41. Kwiatkowski D. Malarial toxins and the regulation of parasite density. *Parasitol Today* 1995; 11: 206-212.

42. Clark IA, Alleva LM, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. *Clin Microbiol Rev* 2004; 17: 509-539.

43. Flori L, Sawadogo S, Esnault C, Delahaye NF, Fumoux F, Rihet P. Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. *Hum Mol Genet* 2003; 12: 375-378.

44. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. *Nature* 1994; 371: 508-510.

45. Meyer CG, May J, Luty AJ, Lell B, Kremsner PG.

TNF α -308A associated with shorter intervals of *Plasmodium falciparum* reinfections. *Tissue Antigens* 2002; 59: 287-292.

46. Aidoo M, McElroy PD, Kolczak MS, Terlouw DJ, Ter-Kuile FO, Nahlen B, et al. Tumor necrosis factor- α promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. *Genet Epidemiol* 2001; 21: 201-211.

47. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, et al. polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. *Nat Genet* 1999; 22: 145-150.

48. Kwiatkowski DP. How Malaria Has Affected the Human Genome and What Human Genetics Can Teach Us about Malaria. *Am. J. Hum. Genet* 2005; 77: 171-190.

49. Ubalee R, Suzuki F, Kikuchi M, Tasanor O, Wattanagoon Y, Ruangweeraayut R, et al. Strong association of a tumor necrosis factor- α promoter allele with cerebral malaria in Myanmar. *Tissue Antigens* 2001; 58: 407-410.

50. Hananantachai H, Patarapotikul J, Ohashi J, Naka I, Krudsood S, Looareesuwan S, Tokunaga K. Significant association between TNF- α (TNF) promoter allele (-1031C, -863C, and -857C) and cerebral malaria in Thailand. *Tissue Antigens* 2007; 69:277-280.

51. Shi YP, Nahlen BL, Kariuki S, Urdahl KB, McElroy PD, Roberts JM, et al. Fc γ Receptor IIa (CD32) Polymorphism is associated with protection of infants against high-density *Plasmodium falciparum* infection. *J Infect Dis* 2001; 184: 107-111.

52. Cooke GC, Aucan C, Walley AJ, Segal S, Greenwood BM, Kwiatkowski DP, et al. Association of Fc γ receptor IIa (CD32) polymorphism with severe malaria in West Africa. *Am J Trop Med Hyg* 2003; 69: 565-568.

53. Nasr A, Iriemenam NC, Troye-Blomberg M, Giha HA, Balogun HA, Osman OF, et al. Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of *Plasmodium falciparum* malaria in Sudanese patients. *Scand J Immunol* 2007; 66: 87-96.

55. Tsai EY, Falvo JV, Tsytsykova AV, Barczak AK, Reimold AM, Glimcher LH, et al. A lipopolysaccharide specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p 300 is recruited to the Tumor Necrosis Factor Alpha promoter in vivo. *Mol Cell Biol* 2000; 20: 6084-6094.

56. Tsytsykova AV, Goldfeld AE. Inducer-specific enhanceosome formation controls Tumor Necrosis Factor Alpha gene expression in T lymphocytes. *Mol Cell Biol* 2002; 22: 2620-2631.

57. Heel DAV, Udalova IA, Silva APD, McGovern D, Kinouchi Y, Hull J, et al. Kwiatkowski D. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF- κ B

transcription factors. *Hum Mol Genet* 2002; 1: 1281-1289.

58. Asghar T, Yoshida S, Kennedy S, Negoro K, Zhuo W, Hamana S, et al. The tumor necrosis factor- α promoter -1031C polymorphism is associated with decreased risk of

endometriosis in a Japanese population. *Hum Rep* 2004; 19: 2509-2514.

60. Cabantous S, Doumbo O, Ranque S, Poudiougou B, Traore A, Hou X, et al. Alleles 308A and 238A in the Tumor Necrosis Factor Alpha gene promoter do not increase the risk of severe malaria in children with *Plasmodium falciparum* infection in Mali. *Infect Immun* 2006; 74: 7040-7042.

61. Sinha SH, Mishra SK, Sharma S, Patibandla PK, Mallick PK, Sharma S.K, et al. Polymorphisms of TNF-enhancer and gene for Fc γ RIIa correlate with the severity of *falciparum* malaria in the ethnically diverse Indian population. *Malaria Journal* 2008; 7:13-18.

62. Richardson A, Sisay-Joof F, Ackerman H, et al. Nucleotide diversity of the TNF gene region in an African village. *Genes Immun* 2002; 2: 343-348.